Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceuticalmanufacturers of finished dosage forms.
Noramco is a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients (APIs) and SPI Pharma is a global leader in the manufacture and supply of functional excipient platforms and the development and licensing of unique dosage forms.
The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies.
Noramco and SPI Pharma will demonstrate proof-of-concept (POC) of a select set of finished drug products in patient-friendly dosage forms, which will be out-licensed to customers for scale-up, registration, and marketing. Customers can also choose upfront to customize formulation packages for specific APIs on a milestone-based, pay-for-success business model.
Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceuticalmanufacturers of finished dosage forms.
Noramco is a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients (APIs) and SPI Pharma is a global leader in the manufacture and supply of functional excipient platforms and the development and licensing of unique dosage forms.
The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies.
Noramco and SPI Pharma will demonstrate proof-of-concept (POC) of a select set of finished drug products in patient-friendly dosage forms, which will be out-licensed to customers for scale-up, registration, and marketing. Customers can also choose upfront to customize formulation packages for specific APIs on a milestone-based, pay-for-success business model.
No comments:
Post a Comment